Knowing that naloxone works by stalling the µ-opioid receptor in an early, latent state suggests that molecules that can bind more tightly or more selectively to this form of the receptor could be ...

Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of ...

Leaders from the Group of 20 countries will meet for a summit in South Africa this weekend without any representatives from ...

The Vitiligo market presents opportunities through 18+ companies developing 20+ pipeline drugs, with a focus on novel approaches. Key phases include Phase III (Afamelanotide), Phase II (VYN201), and ...

Having raised $125 million, the Cochlear-based Epiminder lists next Monday on the back of its groundbreaking epilepsy ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

In an email to federal members of parliament, Association of independently Owned Financial Professionals (AIOFP) executive ...

Amid rising geopolitical tensions, the EU and Japan intensify joint supply-chain monitoring, critical technologies protection, and coordinated investment screening to strengthen their shared economic ...

A commentary published in Brain Medicine by Drs. Julio Licinio and Ma-Li Wong examines groundbreaking research identifying adenosine signaling as the convergent mechanism underlying rapid-acting ...

Pete Whittington discusses efforts to restore metal-contaminated peatlands in Sudbury, Ontario, which were affected by mining ...